Merit Financial Group’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7.26M Sell
57,490
-3,424
-6% -$451K 0.04% 333
2026
Q1
$8.49M Buy
60,914
+7,356
+14% +$1.03M 0.06% 263
2025
Q4
$6.57M Buy
53,558
+5,486
+11% +$667K 0.05% 286
2025
Q3
$5.34M Buy
48,072
+121
+0.3% +$13.8K 0.05% 308
2025
Q2
$5.32M Buy
47,951
+18,722
+64% +$1.99M 0.06% 262
2025
Q1
$3.28M Buy
29,229
+9,522
+48% +$983K 0.05% 298
2024
Q4
$1.82M Buy
19,707
+5,635
+40% +$507K 0.03% 372
2024
Q3
$1.18M Sell
14,072
-1,844
-12% -$141K 0.03% 382
2024
Q2
$1.09M Sell
15,916
-2,885
-15% -$193K 0.02% 385
2024
Q1
$1.22M Buy
18,801
+6,523
+53% +$502K 0.03% 352
2023
Q4
$995K Sell
12,278
-6,994
-36% -$544K 0.03% 318
2023
Q3
$1.44M Sell
19,272
-79
-0.4% -$6.08K 0.05% 268
2023
Q2
$1.49M Buy
19,351
+5,290
+38% +$422K 0.05% 266
2023
Q1
$1.17M Buy
14,061
+2,086
+17% +$173K 0.04% 267
2022
Q4
$1.03M Buy
11,975
+3,114
+35% +$247K 0.04% 292
2022
Q3
$547K Sell
8,861
-6,408
-42% -$404K 0.02% 342
2022
Q2
$944K Buy
+15,269
New +$945K 0.03% 269

Other funds holding GILD

Merit Financial Group's GILD Position: Q2 2026 in Review

Merit Financial Group reduced its Gilead Sciences (GILD) stake by 5.6% in Q2 2026, selling an estimated $451K and leaving 57,490 shares worth $7.26M. The position accounts for 0.04% of the portfolio, ranked #333.

Merit Financial Group first reported a position in GILD in Q2 2022 and has held it in 17 quarters since. The position peaked at $8.49M in Q1 2026. 494 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Merit Financial Group held 57,490 shares of Gilead Sciences worth $7.26M as of Q2 2026.
  • Merit Financial Group sold 3,424 Gilead Sciences shares in Q2 2026, an estimated $451K.
  • Gilead Sciences made up 0.04% of Merit Financial Group's portfolio in Q2 2026, its #333 holding.
  • Merit Financial Group first reported a position in Gilead Sciences in Q2 2022 and has held it in 17 quarters since.
  • Merit Financial Group's Gilead Sciences position peaked at $8.49M in Q1 2026.
  • 494 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Merit Financial Group's 13F filing for Q2 2026, filed 17 Jul 2026.